Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Alkermes Plc (NASDAQ:ALKS) reported strong financial results for the fourth quarter of 2024, surpassing earnings per share (EPS) and revenue forecasts. The company's EPS stood at $1.05, significantly ...